Log in

Relevant bibliographies by topics / Prostate – Cancer – Diagnostic / Journal articles

To see the other types of publications on this topic, follow the link: Prostate – Cancer – Diagnostic.

Journal articles on the topic 'Prostate – Cancer – Diagnostic'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 June 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Prostate – Cancer – Diagnostic.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Nomani, Beenish Hussain, and Mohiuddin Alamgir. "Diagnostic Utility Of Various Biomarkers For Prostate Cancer: A Review." Journal of Bahria University Medical and Dental College 09, no. 02 (2019): 151–55. http://dx.doi.org/10.51985/jbumdc2019015.

Full text

Abstract:

Prostate carcinoma is one of the most widespread occurring cancers in males and is the second most common cause of cancer related mortality in men around the world. The therapeutic success rate for prostate cancer can be greatly improved if the disease is detected at an early stage. Therefore, a successful therapy depends immensely on the clinical indicators (biomarkers) for early diagnosis and progression of the disease, as well as the prognosis after the clinical intervention. Despite of its limitations, prostate biopsy is the “gold standard” for diagnosis of prostatic carcinoma. Beyond the

APA, Harvard, Vancouver, ISO, and other styles

2

Sedláčková, Hana, Olga Dolejšová, Milan Hora, et al. "Prostate Cancer Diagnostic Algorithm as a “Road Map” from the First Stratification of the Patient to the Final Treatment Decision." Life 11, no. 4 (2021): 324. http://dx.doi.org/10.3390/life11040324.

Full text

Abstract:

The diagnostics of prostate cancer are currently based on three pillars: prostate biomarker panel, imaging techniques, and histological verification. This paper presents a diagnostic algorithm that can serve as a “road map”: from initial patient stratification to the final decision regarding treatment. The algorithm is based on a review of the current literature combined with our own experience. Diagnostic algorithms are a feature of an advanced healthcare system in which all steps are consciously coordinated and optimized to ensure the proper individualization of the treatment process. The pr

APA, Harvard, Vancouver, ISO, and other styles

3

Cherkasova, Zh R., S. A. Tsurkan, A. I. Prostyakova, et al. "Potential clinical application of the cancer antigen CA‑62 for differential diagnosis of prostate cancer and benign prostatic hyperplasia at the elevated prostate‑specific antigen." Research and Practical Medicine Journal 10, no. 1 (2023): 10–26. http://dx.doi.org/10.17709/2410-1893-2023-10-1-1.

Full text

Abstract:

Purpose of the study. Evaluation of the diagnostic characteristics of the CA‑62 marker for epithelial carcinomas for detecting early‑stage prostate cancer in a double‑blind clinical study. This study is also focused on the possibility of using the CA‑62 antigen as an auxiliary tool for decision‑making in prostate cancer diagnosis.Patients and methods. A blinded clinical study was conducted on 325 clinically verified blood serum samples. This includes 144 prostate cancer samples, 79 generally healthy volunteers‑men and 102 samples from patients with benign prostatic hyperplasia (BPH). Quantitat

APA, Harvard, Vancouver, ISO, and other styles

4

Tribian, L. S., M. Lennartz, N. C. Blessin, et al. "Diagnostic role and prognostic impact of PSAP immunohistochemistry: A tissue microarray study on 31,358 cancer tissues from 127 different tumor types." American Journal of Clinical Pathology 160, Supplement_1 (2023): S47—S48. http://dx.doi.org/10.1093/ajcp/aqad150.107.

Full text

Abstract:

Abstract Introduction/Objective Prostatic specific acid phosphatase (PSAP) protein is produced in prostate epithelial cells and it is used as an immunohistochemical marker for prostate cancer. However, studies have reported PSAP expression to occur in various other tumor entities as well. Methods/Case Report Prostatic specific acid phosphatase (PSAP) protein is produced in prostate epithelial cells and it is used as an immunohistochemical marker for prostate cancer. However, studies have reported PSAP expression to occur in various other tumor entities as well. Results (if a Case Study enter N

APA, Harvard, Vancouver, ISO, and other styles

5

Tribian, Laura Sophie, Maximilian Lennartz, Doris Höflmayer, et al. "Diagnostic Role and Prognostic Impact of PSAP Immunohistochemistry: A Tissue Microarray Study on 31,358 Cancer Tissues." Diagnostics 13, no. 20 (2023): 3242. http://dx.doi.org/10.3390/diagnostics13203242.

Full text

Abstract:

Prostate-specific acid phosphatase (PSAP) is a marker for prostate cancer. To assess the specificity and prognostic impact of PSAP, 14,137 samples from 127 different tumor (sub)types, 17,747 prostate cancers, and 76 different normal tissue types were analyzed via immunohistochemistry in a tissue microarray format. In normal tissues, PSAP staining was limited to the prostate epithelial cells. In prostate cancers, PSAP was seen in 100% of Gleason 3 + 3, 95.5% of Gleason 4 + 4, 93.8% of recurrent cancer under androgen deprivation therapy, 91.0% of Gleason 5 + 5, and 31.2% of small cell neuroendoc

APA, Harvard, Vancouver, ISO, and other styles

6

Dolgushin, M. B., N. A. Meshcheryakova, A. A. Odzharova, et al. "18F-PSMA-1007 POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN THE DIAGNOSIS OF RECURRENT PROSTATE CANCER: CLINICAL OBSERVATION." Cancer Urology 14, no. 3 (2018): 134–38. http://dx.doi.org/10.17650/1726-9776-2018-14-3-134-138.

Full text

Abstract:

Objective: demonstration of possibilities of18F-prostate specific membrane antigen-1007 (18F-PSMA-1007) positron emission tomography/computed tomography (PET/CT) for diagnostic prostate cancer recurrence.The article presents clinical observation of the patient with prostate cancer biochemical recurrence after the multiple treatment.18F-PSMA-1007 PET/CT demonstrates high sensitivity in prostate cancer recurrence diagnostic, in particular with low prostatic specific antigen level.

APA, Harvard, Vancouver, ISO, and other styles

7

Viehweger, F., M. Lennartz, N. C. Blessin, et al. "Prostein expression in human tumors: A tissue microarray study on 19,202 tumors." American Journal of Clinical Pathology 160, Supplement_1 (2023): S45. http://dx.doi.org/10.1093/ajcp/aqad150.101.

Full text

Abstract:

Abstract Introduction/Objective Prostein (P501S), also termed solute carrier family 45 member 3 (SLC45A3) is an androgen regulated protein which is preferentially expressed in prostate epithelial cells. Because of its frequent expression in prostate cancer, prostein was suggested a diagnostic prostate cancer marker. Methods/Case Report In order to comprehensively assess the diagnostic utility of prostein immunohistochemistry, a tissue microarray containing 19,202 samples from 152 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immun

APA, Harvard, Vancouver, ISO, and other styles

8

Mahaveer Chand, Nischal, Poornima K. Tekumalla, Matt T. Rosenberg, et al. "Filamin A Is a Prognostic Serum Biomarker for Differentiating Benign Prostatic Hyperplasia from Prostate Cancer in Caucasian and African American Men." Cancers 16, no. 4 (2024): 712. http://dx.doi.org/10.3390/cancers16040712.

Full text

Abstract:

Prostate cancer represents a significant health risk to aging men, in which diagnostic challenges to the identification of aggressive cancers remain unmet. Prostate cancer screening is driven by the prostate-specific antigen (PSA); however, in men with benign prostatic hyperplasia (BPH) due to an enlarged prostate and elevated PSA, PSA’s screening utility is diminished, resulting in many unnecessary biopsies. To address this issue, we previously identified a cleaved fragment of Filamin A (FLNA) protein (as measured with IP-MRM mass spectrometry assessment as a prognostic biomarker for stratify

APA, Harvard, Vancouver, ISO, and other styles

9

Dülgeroğlu, Yakup, Gönül Erden, Musa Ekici, et al. "Diagnostic efficiency of miR-21 and miR-34a serum levels in malign and benign prostate diseases." Yeni Üroloji Dergisi 16, no. 3 (2021): 221–27. http://dx.doi.org/10.33719/yud.2021;16-3-865045.

Full text

Abstract:

Objective: In this study aimed to determine the diagnostic efficiency of miR-21 and miR-34a serum levels in the discrimination of benign prostatic hyperplasia, chronic prostatitis, and prostate cancer. Materials and Methods: Blood samples were taken from 70 patients (25 benign prostatic hyperplasias, 10 chronic prostatitides, and 35 prostate cancer) who underwent prostate needle biopsy. After obtaining serum under suitable conditions, RNA isolation, cDNA synthesis, and qRT-PCR analysis were performed using Qiagen brand kits on Rotor-Gene® Q (Qiagen, Germany) device. -∆Ct values were calculat

APA, Harvard, Vancouver, ISO, and other styles

10

Leonova, A. O., E. I. Kopyltsov, B. Ya Alekseev, et al. "Medical, social, and economic perspectives of health care development. Prostate Cancer Early Diagnosis and Screening Program." Cancer Urology 18, no. 2 (2022): 217–25. http://dx.doi.org/10.17650/1726-9776-2022-18-2-217-225.

Full text

Abstract:

Aim. To improve diagnostics and screening of prostate cancer to ensure early detection of malignant tumors.Materials and methods. We analyzed the population size and structure in the region in 2005–2010. The primary diagnostics of prostate cancer in regional healthcare institutions allowed the detection of locally advanced tumors and generalized cancer. Such diagnostic approaches can produce only accidental diagnosis since they lack proper systematization, organization, and control.Results. We have developed and implemented into clinical practice a long-term Program for Prostate Cancer Early D

APA, Harvard, Vancouver, ISO, and other styles

11

Bashir, Qamar, Zujaja Hina Haroon, Naveed Asif, Azka Haroon, Muhammad Asif, and Syed Raza Jaffar. "Diagnostic Accuracy of Prostatic Specific Antigen Densityin Different Prostatic Disorders." Pakistan Armed Forces Medical Journal 72, no. 4 (2022): 1236–40. http://dx.doi.org/10.51253/pafmj.v72i4.5670.

Full text

Abstract:

Objective: To determine the diagnostic accuracy of PSA density in Prostate Cancer, Benign Prostatic Hyperplasia (BPH) and Prostatitis, taking biopsy as the gold standard. Study Design: Cross-sectional study. Place and Duration of Study: Chemical Pathology and Endocrinology Department, Armed Forces Institute of Pathology (AFIP) in collaboration with Histopathology department, AFIP, Armed Forces Institute of Urology (AFIU) and Institute of Radiology (AFIRI) Rawalpindi Pakistan from Mar 2019 to Mar 2020. Methodology: Prostate-specific antigen was analyzed on a fully automated ra

APA, Harvard, Vancouver, ISO, and other styles

12

Plichta, Kristin A., Stephen A. Graves, and John M. Buatti. "Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer." International Journal of Molecular Sciences 22, no. 22 (2021): 12095. http://dx.doi.org/10.3390/ijms222212095.

Full text

Abstract:

Theranostics, a combination of therapy and diagnostics, is a field of personalized medicine involving the use of the same or similar radiopharmaceutical agents for the diagnosis and treatment of patients. Prostate-specific membrane antigen (PSMA) is a promising theranostic target for the treatment of prostate cancers. Diagnostic PSMA radiopharmaceuticals are currently used for staging and diagnosis of prostate cancers, and imaging can predict response to therapeutic PSMA radiopharmaceuticals. While mainly used in the setting of metastatic, castrate-resistant disease, clinical trials are invest

APA, Harvard, Vancouver, ISO, and other styles

13

Saedi, Mohammad S., Timothy M. Hill, Kristine Kuus-Reichel, et al. "The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia." Clinical Chemistry 44, no. 10 (1998): 2115–19. http://dx.doi.org/10.1093/clinchem/44.10.2115.

Full text

Abstract:

Abstract Prostate-specific antigen (PSA, hK3) is a diagnostic marker for prostatic cancer but lacks the specificity to sufficiently distinguish between prostatic cancer and benign prostatic hyperplasia (BPH). Human glandular kallikrein 2 (hK2) has been proposed as a potential diagnostic marker for prostate cancer that could complement the current PSA test. Recently we demonstrated that proPSA is present in prostate cancer sera. This study examines the expression of prohK2 in prostate cells and its presence in human sera. Western blot analysis was used to assess prohK2 expression in the human c

APA, Harvard, Vancouver, ISO, and other styles

14

Pyda-Karwicka, Maria, Malwina Karwicka, Janusz Kopczyński, et al. "Current status and new approaches in prostate cancer diagnosis." Polish Journal of Public Health 128, no. 4 (2018): 166–69. http://dx.doi.org/10.2478/pjph-2018-0033.

Full text

Abstract:

Abstract Prostate adenocarcinoma, remaining among top most common cancers, is a heterogeneous group of tumors with a diverse morphological structure. Basing on the histological architecture of cancer tissue, individual cases can be classified into different therapeutic groups. Current diagnosis of prostate cancer brings many challenges. The major problem is the lack of effective and accessible diagnostic methods that would eliminate incidences of overdiagnosis and prevent unnecessary treatments of many patients. There are many efforts to determine favorable and unfavorable molecular prognostic

APA, Harvard, Vancouver, ISO, and other styles

15

Rahman, Md Tahminur, and ATM Mowladad Chowdhury. "Prostate Cancer." Anwer Khan Modern Medical College Journal 7, no. 2 (2017): 36–44. http://dx.doi.org/10.3329/akmmcj.v7i2.31644.

Full text

Abstract:

Prostate cancer is the number one cancer by incidence in males of increasing age & second by mortality throughout the world. Many known etiological factors are associated with increased risk of prostatic carcinoma including male hormone & its active metabolites, genetic predisposition (BRCA2, inherited polymorphism of some transcription factors), racial difference, environmental factors, food habits etc, Recently an association of importance has been given to molecular level changes; inflammatory cytokines, trace elements like zinc with prostate cancer. Diagnostic modalities & trea

APA, Harvard, Vancouver, ISO, and other styles

16

Stepanov, N., Z. Duvayarov, I, Bystrova, T. Chepaikina, and V. Kostrova. "Optimization of Early Diagnostics of Prostate Cancer." Bulletin of Science and Practice 6, no. 5 (2020): 97–104. http://dx.doi.org/10.33619/2414-2948/54/12.

Full text

Abstract:

The prevalence and incidence of prostate cancer is gradually increasing both in our country and in countries near and far abroad. The difficulties in the differential diagnosis of prostate cancer are convincingly evidenced by the fact that the level of diagnostic errors reaches 40%. It should be noted that in assessing the differential diagnostic capabilities of the indicators of the clinical and special examination methods for patients with lower urinary tract symptoms, disagreements were found in 46–77% of the analyzed clinical signs, the changes of which mainly reflect the negative nature o

APA, Harvard, Vancouver, ISO, and other styles

17

Perincheri, Sudhir, Angelique Wolf Levi, Romulo Celli, et al. "An independent assessment of an artificial intelligence system for prostate cancer detection shows strong diagnostic accuracy." Modern Pathology 34, no. 8 (2021): 1588–95. http://dx.doi.org/10.1038/s41379-021-00794-x.

Full text

Abstract:

AbstractProstate cancer is a leading cause of morbidity and mortality for adult males in the US. The diagnosis of prostate carcinoma is usually made on prostate core needle biopsies obtained through a transrectal approach. These biopsies may account for a significant portion of the pathologists’ workload, yet variability in the experience and expertise, as well as fatigue of the pathologist may adversely affect the reliability of cancer detection. Machine-learning algorithms are increasingly being developed as tools to aid and improve diagnostic accuracy in anatomic pathology. The Paige Prosta

APA, Harvard, Vancouver, ISO, and other styles

18

Basavaraj, Dr Rashmi G. S., and Dr Ravikumar Malladad. "Association of serum prostate-specific antigen with Complete Blood Counts in patients with prostatic cancer." Tropical Journal of Pathology and Microbiology 7, no. 4 (2021): 162–69. http://dx.doi.org/10.17511/jopm.2021.i04.02.

Full text

Abstract:

Background: Prostate cancer is the second most common cancer and one of the most leadingcauses of death in men worldwide. The prostate-specific antigen (PSA) as a screening methodshowed that there has been a slight decrease in prostate cancer mortality. Effective biomarkers inscreening and diagnosis would be beneficial for avoiding unnecessary operations. The predictive andprognostic value of complete blood count (CBC) has been manifested by recent studies. We aimed todetermine the association of serum PSA with Complete blood counts in patients with prostate cancer.Method: The present study in

APA, Harvard, Vancouver, ISO, and other styles

19

Chand, Nischal Mahaveer, Poornima K. Tekumalla, Albert Dobi, et al. "Abstract 2196: Serum Filamin A is a prognostic biomarker for screening benign prostatic hyperplasia vs prostate cancer in Caucasian and African American men." Cancer Research 83, no. 7_Supplement (2023): 2196. http://dx.doi.org/10.1158/1538-7445.am2023-2196.

Full text

Abstract:

Abstract Prostate cancer represents a significant health risk to aging men, in which diagnostic challenges pose major issues with identification of indolent and or aggressive cancers. Prostate cancer screening is driven by prostate specific antigen (PSA), however, PSA’s screening utility is diminished in men with benign prostatic hyperplasia (BPH) due to an enlarged prostate and elevated PSA, triggering unnecessary biopsies in men with this condition. Thus, there is a critical unmet medical need to identify a marker for men with these conditions. Moreover, it is crucial to test any novel bioma

APA, Harvard, Vancouver, ISO, and other styles

20

Adhyatma, Kharisma Prasetya, and Syah Mirsya Warli. "Diagnostic Value of Platelet–To-Lymphocyte Ratio in Prostate Cancer." Open Access Macedonian Journal of Medical Sciences 7, no. 7 (2019): 1093–96. http://dx.doi.org/10.3889/oamjms.2019.252.

Full text

Abstract:

BACKGROUND: Previous studies demonstrated the promising value of platelet-to-lymphocyte (PLR) in prostate cancer. AIM: This study was conducted to evaluate its pre-biopsy values in predicting prostate cancer. METHODS: We included all benign prostatic hyperplasia (BPH) and prostate cancer (PCa) patients who underwent a prostate biopsy in Adam Malik Hospital between August 11th 2011 and August 31st 2015. The relationship between pre-biopsy variables which could be affecting the percentage of prostate cancer risk was evaluated, including age, prostate-specific antigen (PSA) level, and

APA, Harvard, Vancouver, ISO, and other styles

21

Floares, Alexandru George, Adrian Vasile Zety, Carmen Floares, George Calin, Eduardo Kreutz Carvalho, and Florin Manolache. "i-Biomarker CaDx: A circulating miRNA-based multi-cancer detection tool with explainable AI for prostate cancer." Journal of Clinical Oncology 42, no. 4_suppl (2024): 272. http://dx.doi.org/10.1200/jco.2024.42.4_suppl.272.

Full text

Abstract:

272 Background: Prostate cancer is a pressing concern, demanding early and accurate detection for effective intervention. Conventional methods, like digital rectal exams and prostate-specific antigen (PSA) tests, often lack the required specificity. Circulating microRNAs (miRNAs) have emerged as promising non-invasive biomarkers for various cancers, including prostate cancer. The i-Biomarker CaDx is a cutting-edge, technology-neutral platform designed for multi-cancer early detection, boasting an impressive accuracy rate of 99-100%. This study aims to assess the effectiveness of i-Biomarker Ca

APA, Harvard, Vancouver, ISO, and other styles

22

S. Hassan, Intisar, Abdulkarem Y. Suleiman, and Bashar A. Hassawi. "Diagnostic Yield of Transu rethral resection of prostatetransu rethral r esection of bladder tumor TURP and(TURBT) in Mosul Two Years Study." Tikrit Journal of Pharmaceutical Sciences 6, no. 2 (2023): 138–46. http://dx.doi.org/10.25130/tjphs.2010.6.2.7.138.146.

Full text

Abstract:

Yield of TURP-TURBT (lransurethral resection of prostate transurethmal resection of bladder tumor) in Mosul has not been studied before. Prostatic & bladder cancers are increasing in this specific locality, to know their frequency and grades this study was donc. Four hundred and ninety TURP-TURBT chips were received, examined grossly, processed routinely, and then analyzed microscopically. The study was performed in Alzahrawi hospital - histopathology laboratories of Mosul city in Iraq between January 2006 and through December 2007. There were 320 (65.3%) were taken hy TURP and 170 (34.7%)

APA, Harvard, Vancouver, ISO, and other styles

23

Häggarth, Lars, Christina Hägglöf, Sara Jonmarker Jaraj, et al. "Diagnostic biomarkers of prostate cancer." Scandinavian Journal of Urology and Nephrology 45, no. 1 (2010): 60–67. http://dx.doi.org/10.3109/00365599.2010.526141.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Gardner, William A., Donald Coffey, James P. Karr, et al. "Diagnostic Nomenclature for Prostate Cancer." Journal of Urology 138, no. 6 (1987): 1436. http://dx.doi.org/10.1016/s0022-5347(17)43667-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Djavan, Bob, Amir Kazzazi, Lori Dulabon, et al. "Diagnostic Strategies for Prostate Cancer." European Urology Supplements 10, no. 3 (2011): e26-e37. http://dx.doi.org/10.1016/j.eursup.2011.03.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Khalikovich, Khushnazarov Khasan. "THE ROLE AND SIGNIFICANCE OF COMPRESSION ELASTOGRAPHY IN THE EARLY DIAGNOSIS OF PROSTATE CANCER." Frontline Medical Sciences and Pharmaceutical Journal 02, no. 12 (2022): 20–28. http://dx.doi.org/10.37547/medical-fmspj-02-12-02.

Full text

Abstract:

The research paper presents the results of diagnostics and treatment of 96 patients with focal formations of the prostate. Based on the conducted complex ultrasound studies of patients, the authors define the main specific diagnostic criteria, the use of which allows to detect prostate cancer in the early stages.

APA, Harvard, Vancouver, ISO, and other styles

27

Fredsøe, Jacob, Anne K. I. Rasmussen, Peter Mouritzen, et al. "Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential." Diagnostics 10, no. 4 (2020): 188. http://dx.doi.org/10.3390/diagnostics10040188.

Full text

Abstract:

Early detection of prostate cancer (PC) is paramount as localized disease is generally curable, while metastatic PC is generally incurable. There is a need for improved, minimally invasive biomarkers as current diagnostic tools are inaccurate, leading to extensive overtreatment while still missing some clinically significant cancers. Consequently, we profiled the expression levels of 92 selected microRNAs by RT-qPCR in plasma samples from 753 patients, representing multiple stages of PC and non-cancer controls. First, we compared plasma miRNA levels in patients with benign prostatic hyperplasi

APA, Harvard, Vancouver, ISO, and other styles

28

Maddalone, Maria Grazia, Marco Oderda, Giulio Mengozzi, et al. "Urinary Zinc Loss Identifies Prostate Cancer Patients." Cancers 14, no. 21 (2022): 5316. http://dx.doi.org/10.3390/cancers14215316.

Full text

Abstract:

Prostate Cancer (PCa) is one of the most common malignancies in men worldwide, with 1.4 million diagnoses and 310,000 deaths in 2020. Currently, there is an intense debate regarding the serum prostatic specific antigen (PSA) test as a diagnostic tool in PCa due to the lack of specificity and high prevalence of over-diagnosis and over-treatments. One of the most consistent characteristics of PCa is the marked decrease in zinc; hence the lost ability to accumulate and secrete zinc represents a potential parameter for early detection of the disease. We quantified zinc levels in urine samples coll

APA, Harvard, Vancouver, ISO, and other styles

29

Andrian, Andrian, Adistra Imam Satjakoesoemah, Rochani Sumardi, Sahat B. R. E. Matondang, and Meilania Saraswati. "Case Report: High-grade anterior prostate cancer previously undetected by transrectal biopsy, diagnosed with MRI-US fusion transperineal robotic prostate biopsy." F1000Research 11 (February 28, 2022): 247. http://dx.doi.org/10.12688/f1000research.109546.1.

Full text

Abstract:

Seventy percent of anterior prostate cancer cases are diagnosed during rebiopsy. MRI-US fusion transperineal robotic prostate biopsy is an emerging diagnostic method and might be an effective one in diagnosing prostate cancers in difficult sites such as the anterior zone. We report a case of a high grade anterior prostate cancer previously undetected by transrectal biopsy, diagnosed with MRI-US fusion transperineal robotic prostate biopsy. This case report suggests that MRI-US fusion transperineal robotic prostate biopsy might be valuable in diagnosing prostate cancer especially in difficult s

APA, Harvard, Vancouver, ISO, and other styles

30

Opoku Mensah, Bismark, Linda Ahenkorah Fondjo, W. K. B. A. Owiredu, and Ben Adusei. "Urinary PCA3 a Superior Diagnostic Biomarker for Prostate Cancer among Ghanaian Men." Disease Markers 2022 (October 7, 2022): 1–10. http://dx.doi.org/10.1155/2022/1686991.

Full text

Abstract:

Introduction. Prostate cancer is one of the most commonly diagnosed cancers in men. Prostate-specific antigen (PSA) has been the biomarker of choice for screening and diagnosis of prostate cancer. However, inefficiencies exist with its diagnostic capabilities. This study thus evaluated the diagnostic and prognostic potential of urinary PCA3 as an alternative biomarker for prostate cancer in the Ghanaian population. Methods. A hospital-based cross-sectional study was conducted at the Urology Department of the 37 Military Hospital, Accra, Ghana. A total of 237 participants aged 40 years and abov

APA, Harvard, Vancouver, ISO, and other styles

31

Islam, Md Azizul, S. M. Shahinul Islam, Md Jawadul Haque, and Md Mokter Hossain. "Ability of Free/Total Serum PSA Ratio in Diagnosing Prostate Cancer and Benign Prostatic Hyperplasia." TAJ: Journal of Teachers Association 36, no. 2 (2023): 101–9. http://dx.doi.org/10.3329/taj.v36i2.71537.

Full text

Abstract:

Background: The Prostate gland is the male secondary sexual organ most commonly affected by benign or malignant neoplasm. Prostate cancer (Ca-P) is one of the most commonly diagnosed cancers in men and is now the third commonest cause of cancer death in western countries. The aim of the study was to evaluate the use of serum prostate-specific antigen levels in differentiating prostate cancer from benign prostatic hyperplasia. Methods: The present study is a cross-sectional observational study. The study was conducted at the outpatient department and indoor patients at the department of Urology

APA, Harvard, Vancouver, ISO, and other styles

32

Jung, Klaus, Brigitte Brux, Michael Lein, et al. "Molecular Forms of Prostate-specific Antigen in Malignant and Benign Prostatic Tissue: Biochemical and Diagnostic Implications." Clinical Chemistry 46, no. 1 (2000): 47–54. http://dx.doi.org/10.1093/clinchem/46.1.47.

Full text

Abstract:

Abstract Background: Patients with prostate cancer (PCa) show a lower ratio of free prostate-specific antigen (fPSA) to total PSA (tPSA) in serum than patients with benign prostatic hyperplasia (BPH). The patterns of the intracellular PSA isoforms in malignant and benign prostatic tissue have been studied as potential molecular reasons for this phenomenon. Methods: Prostatic tissue samples were obtained after cystoprostatectomy from patients with bladder cancer (n = 10), from BPH patients (transurethral resection of the prostate, n = 10; adenomectomy, n = 10), and from the cancerous and noncan

APA, Harvard, Vancouver, ISO, and other styles

33

Kanan, Christopher, Jillian Sue, Leo Grady, et al. "Independent validation of paige prostate: Assessing clinical benefit of an artificial intelligence tool within a digital diagnostic pathology laboratory workflow." Journal of Clinical Oncology 38, no. 15_suppl (2020): e14076-e14076. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e14076.

Full text

Abstract:

e14076 Background: The most common approach to diagnose prostate cancer is the “whole gland biopsy procedure,” in which numerous cores (≥12) are taken from different regions of the gland to maximize the chances of detecting small cancers; the presence of cancer in any of these cores is significant to the patient. If concerning features that are not fully diagnostic of cancer are identified, the pathologist may defer the final diagnosis until additional studies (e.g. immunohistochemistry) have been performed. We recently developed an artificial intelligence (AI)-based system for the assessment

APA, Harvard, Vancouver, ISO, and other styles

34

Shrestha, Reshmi, Shova Kunwar, Suman Gurung, and Anjana Nuri Pokharel. "Usefulness of prostate specific antigen density in detecting prostate carcinoma: A hospital-based study in patients with prostate biopsies." Journal of Pathology of Nepal 12, no. 1 (2022): 1907–13. http://dx.doi.org/10.3126/jpn.v12i1.41841.

Full text

Abstract:

Background: Prostate-specific antigen density has been suggested to enhance the diagnostic efficacy of serum prostate-specific antigen alone in detecting prostate cancer, thereby reducing unnecessary biopsies and associated morbidities. This study aimed to assess the diagnostic performance of prostate-specific antigen density in detecting prostate cancer. Materials and methods: A retrospective analysis of histologically proven benign and malignant prostate diseases, submitted in the histopathology department was performed from April 2019 to March 2020. The diagnostic performance of prostate-sp

APA, Harvard, Vancouver, ISO, and other styles

35

Mijović, Milica, Vladica Nedeljković, Danica Vukićević, et al. "Diagnostic, prognostic and predictive parameters in prostate cancer." Praxis medica 49, no. 3-4 (2020): 43–49. http://dx.doi.org/10.5937/pramed2004043m.

Full text

Abstract:

Prostate cancer (CP) is the most common malignancy in men in America, while it is the second most common in Europe. It is responsible for about 10% of cancer deaths in the same population. It is clinically manifested in various forms, from slow-growing to aggressive forms with pronounced metastatic potential. Diagnosis is made by a well-defined algorithm, which begins with the determination of serum prostate specific antigen values and ends with prostate biopsy as the "gold standard". Pathohistological diagnostic criterias are based on architectural, cytoplasmic, nuclear and characteristics of

APA, Harvard, Vancouver, ISO, and other styles

36

Islam, Md Azizul, S. M. Shahinul Islam, Md Jawadul Haque, and Md Mokter Hossain. "Assessment the Ability of Free/Total Ratio of Serum PSA in Diagnosing Prostate Cancer and Benign Prostatic Hyperplasia." TAJ: Journal of Teachers Association 36, no. 2 (2023): 215–24. http://dx.doi.org/10.3329/taj.v36i2.72511.

Full text

Abstract:

Background: The Prostate gland is the male secondary sexual organ most commonly affected by benign or malignant neoplasm. Prostate cancer (Ca-P) is one of the most commonly diagnosed cancers in men and is now the third commonest cause of cancer death in western countries.The aim of the study was to evaluate the use of serum prostate-specific antigen levels in differentiating prostate cancer from benign prostatic hyperplasia. Methods:The present study is a cross-sectional observational study.The study was conducted at the outpatient department and indoor patients at the department of Urology, R

APA, Harvard, Vancouver, ISO, and other styles

37

Koistinen, Hannu, Ruusu-Maaria Kovanen, Timo-Pekka Lehto, Antti Rannikko, and Tuomas Mirtti. "Abstract 5551: Cancer associated PSA-glycoforms as prostate cancer markers." Cancer Research 83, no. 7_Supplement (2023): 5551. http://dx.doi.org/10.1158/1538-7445.am2023-5551.

Full text

Abstract:

Abstract Changes in protein glycosylation have been observed in several cancers, where they affect cellular growth behavior, invasiveness and acquisition of metastatic potential. Such changes are not random and have been found to associate with cancer aggressiveness. Thus, detection of protein glycosylation may offer novel opportunities for cancer biomarker development. Since prostate-specific antigen (PSA) is glycosylated, assessing different PSA-glycoforms may provide valuable diagnostic and prognostic information. We recently established a novel in situ proximity ligation-based method for t

APA, Harvard, Vancouver, ISO, and other styles

38

Ayyad, Sarah M., Mohamed A. Badawy, Mohamed Shehata, et al. "A New Framework for Precise Identification of Prostatic Adenocarcinoma." Sensors 22, no. 5 (2022): 1848. http://dx.doi.org/10.3390/s22051848.

Full text

Abstract:

Prostate cancer, which is also known as prostatic adenocarcinoma, is an unconstrained growth of epithelial cells in the prostate and has become one of the leading causes of cancer-related death worldwide. The survival of patients with prostate cancer relies on detection at an early, treatable stage. In this paper, we introduce a new comprehensive framework to precisely differentiate between malignant and benign prostate cancer. This framework proposes a noninvasive computer-aided diagnosis system that integrates two imaging modalities of MR (diffusion-weighted (DW) and T2-weighted (T2W)). For

APA, Harvard, Vancouver, ISO, and other styles

39

Tarabayeva, A. S., A. B. Zhubanturliyeva, and I. M. Okhas. "Modern prostate cancer biomarkers. Prospects for EN2 in the prostate cancer diagnosis." Cancer Urology 16, no. 3 (2020): 165–73. http://dx.doi.org/10.17650/1726-9776-2020-16-3-165-173.

Full text

Abstract:

Prostate cancer is one of the most common forms of malignant neoplasms in men. In this regard, it is relevant to search for diagnostic markers that allow the creation of inexpensive, effective tests for early diagnosis of the disease, predicting the risk of relapse and assessing the effectiveness of the therapy. Existing invasive methods for diagnosing prostate cancer present some difficulties for patients. This article discusses the diagnostic capabilities of tissue biomarkers of prostate cancer obtained by non-invasive methods.

APA, Harvard, Vancouver, ISO, and other styles

40

Tokas, Theodoros. "Special Issue “Prostate Cancer: Recent Advances in Diagnostics and Treatment Planning”." Journal of Clinical Medicine 11, no. 22 (2022): 6823. http://dx.doi.org/10.3390/jcm11226823.

Full text

Abstract:

This editorial of the Special Issue “Prostate Cancer: Recent Advances in Diagnostics and Treatment Planning” aims to draw more attention to the broad and diverse field of prostate cancer (PCa) diagnosis and the utilization of different diagnostic means to improve clinical decision-making and treatment strategy planning [...]

APA, Harvard, Vancouver, ISO, and other styles

41

Martignano, Filippo, Giorgia Gurioli, Samanta Salvi, et al. "GSTP1Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications." Disease Markers 2016 (2016): 1–6. http://dx.doi.org/10.1155/2016/4358292.

Full text

Abstract:

GSTP1belongs to the GSTs family, a group of enzymes involved in detoxification of exogenous substances and it also plays an important role in cell cycle regulation. Its dysregulation correlates with a large variety of tumors, in particular with prostate cancer. We investigatedGSTP1methylation status with methylation specific PCR (MS-PCR) in prostate cancer (PCa) and in benign tissue of 56 prostatectomies. We also performed immunohistochemistry (IHC) so as to correlate gene methylation with gene silencing.GSTP1appears methylated in PCa and not in healthy tissue; IHC confirmed that methylation l

APA, Harvard, Vancouver, ISO, and other styles

42

Aboian, I. A., E. N. Fedotova, A. N. Shevchenko, et al. "Current biomarkers of prostate cancer." Research and Practical Medicine Journal 8, no. 4 (2021): 96–108. http://dx.doi.org/10.17709/2410-1893-2021-8-4-10.

Full text

Abstract:

Prostate cancer is one of the most common malignancies in men. Early detection of prostate cancer is largely determined by the widely used prostate specific antigen (PSA) blood test. However, as a diagnostic and prognostic test of prostate cancer, PSA has limited specificity, sensitivity and leads to hyper or underdiagnosis, which, in turn, can lead to excessive treatment. There fore, it is very important to develop diagnostic markers that can be used to determine prostate cancer at an early stage of development, assess the possible progression of the disease and prescribe optimal therapy. Sig

APA, Harvard, Vancouver, ISO, and other styles

43

Ullrich, Tim, Lars Schimmöller, Mathias Oymanns, et al. "Current Utilization and Acceptance of Multiparametric MRI in the Diagnosis of Prostate Cancer. A Regional Survey." RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren 190, no. 05 (2017): 419–26. http://dx.doi.org/10.1055/s-0043-118128.

Full text

Abstract:

Purpose To assess the current regional acceptance, valuation, and clinical role of multiparametric MRI (mp-MRI) in prostate cancer diagnostics by patients and physicians. Materials and Methods Of 482 distributed standardized questionnaires, 328 patient and 31 physician questionnaires (urological and general practitioners in and around Düsseldorf) were analyzed over a period of 11 months. Questions were asked concerning general knowledge about prostate cancer, current diagnostic procedures, and knowledge about mp-MRI and MRI-guided biopsy. Results 70 % of the patients regarded accurate and exac

APA, Harvard, Vancouver, ISO, and other styles

44

Coppola, Valeria, Ruggero De Maria, and Désirée Bonci. "MicroRNAs and prostate cancer." Endocrine-Related Cancer 17, no. 1 (2010): F1—F17. http://dx.doi.org/10.1677/erc-09-0172.

Full text

Abstract:

Despite much progress in prostate cancer management, new diagnostic, prognostic and therapeutic tools are needed to predict disease severity, choose among the available treatments and establish more effective therapies for advanced prostate cancer. In the last few years, compelling evidence has documented the role of microRNAs as new broad-spectrum oncogenes or tumour suppressor genes, thus their use as diagnostic, prognostic and therapeutic biomolecules is envisaged. This review extensively and critically summarizes the current knowledge about microRNA deregulation in prostate cancer disease,

APA, Harvard, Vancouver, ISO, and other styles

45

Wasim, Sobia, Sang-Yoon Lee, and Jaehong Kim. "Complexities of Prostate Cancer." International Journal of Molecular Sciences 23, no. 22 (2022): 14257. http://dx.doi.org/10.3390/ijms232214257.

Full text

Abstract:

Prostate cancer has a long disease history and a wide variety and uncertainty in individual patients’ clinical progress. In recent years, we have seen a revolutionary advance in both prostate cancer patient care and in the research field. The power of deep sequencing has provided cistromic and transcriptomic knowledge of prostate cancer that has not discovered before. Our understanding of prostate cancer biology, from bedside and molecular imaging techniques, has also been greatly advanced. It is important that our current theragnostic schemes, including our diagnostic modalities, therapeutic

APA, Harvard, Vancouver, ISO, and other styles

46

Makau-Barasa, Louise K., Achille Manirakiza, Andre L. Carvalho, and Timothy R. Rebbeck. "Prostate Cancer Screening, Diagnostic, Treatment Procedures and Costs in Sub-Saharan Africa: A Situational Analysis." Cancer Control 29 (January 2022): 107327482210849. http://dx.doi.org/10.1177/10732748221084932.

Full text

Abstract:

Purpose Prostate cancer mortality is predicted to nearly double by 2040 in Sub-Saharan Africa (SSA). The lack of prostate cancer screening in SSA contributes to late-stage diagnosis, treatment delays, and poor survival among patients. We analyzed the availability and use of prostate cancer screening, diagnostic and treatment guidelines, procedures, and costs in few SSA countries to determine factors for consideration in the development of prostate cancer screening guidelines for SSA. Methods We applied mixed methods approaches to collect data through an electronic survey administered to clinic

APA, Harvard, Vancouver, ISO, and other styles

47

Hobbs, Matthew David, Natalia Norori, Thomas Harding, and Amy Rylance. "Prostate cancer screening: Have we tipped the seesaw?" Journal of Clinical Oncology 41, no. 6_suppl (2023): 43. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.43.

Full text

Abstract:

43 Background: Screening for prostate cancer has been and remains contentious with evidence of harms and benefits finely balanced and inadequate to tip the see saw one way or another in order to give men clear, understandable guidance on PSA testing. In recent years the diagnostic pathway has changed significantly delivering a modern pathway that is likely to do far less harm and possibly more benefit. Our work quantifies the levels of harm and benefit at each stage of the entire pathway currently used in the UK from initial PSA through to biopsy-confirmed diagnosis of prostate cancer. Methods

APA, Harvard, Vancouver, ISO, and other styles

48

Qureshi, Salman Manzoor, Muhammad Ali Sohail, Mujeeb ur Rehman Sahito, and Aijaz Hussain Memon. "To determine the frequency of prostate malignancy in patients with clinically benign prostate." Professional Medical Journal 26, no. 08 (2019): 1289–95. http://dx.doi.org/10.29309/tpmj/2019.26.08.3871.

Full text

Abstract:

To see the frequency of prostatic malignancy in patients presenting with clinically benign prostate. Study Design: Descriptive case series. Setting: Department of Urology at Peoples University of Medical and Health Sciences for Women / Hospital Nawabshah. Period: Fifteen Months, From October 2016 to December 2017. Materials and Methods: A total of 100 patients who presented with the clinically benign prostate in Urology OPD were enrolled. All concern data regarding Age, mode of presentation (lower urinary tract symptoms with IPSS score/ Acute retention of urine), comorbid, clinical examination

APA, Harvard, Vancouver, ISO, and other styles

49

Grigore, Nicolae, Valentin Pirvut, Ionela Mihai, Adrian Hasegan, and Sebastian Ioan Cernusca Mitariu. "Prostatic Specific Antigen Less then 10 ng/mL in the Diagnostic and Surveillance of Prostate Cancer." Revista de Chimie 68, no. 5 (2017): 933–36. http://dx.doi.org/10.37358/rc.17.5.5584.

Full text

Abstract:

Prostate cancer (PCa) is the most commonly diagnosed male malignancy after 60 years old. Today, the problem is to distinguish between low-risk and agrressive cancers, especially in patients with Prostatic Specific Antigen (PSA) less than 10 ng/ml The use of PSA as a biomarkers for diagnosis and prognosis of prostate cancer has the potential to improve the clinical management of the patients. PSA levels. together with clinical examination, prostate ultrasound and histopatological examination are esential for the diagnostic of PCa, risk assessment and therapeutic decisions. The aim of our study

APA, Harvard, Vancouver, ISO, and other styles

50

Dong, Hang, Haoran Tang, Yue Zhang, and Shidong Jia. "Abstract 4745: Prostatic fluid-based cfDNA methylation profiling distinguish benign hyperplasia from prostate cancer." Cancer Research 83, no. 7_Supplement (2023): 4745. http://dx.doi.org/10.1158/1538-7445.am2023-4745.

Full text

Abstract:

Abstract Introduction: A challenge in the early diagnosis of prostate cancer (PC) is to distinguish between malignant tumor and benign prostatic hyperplasia (BPH) because of the similar symptoms. Methylation profiles provide a way for discriminating BPH from PC, which could prevent overdiagnosis and overtreatment. Applying methylation biomarkers to liquid biopsy specimens provides higher sensitivity to detect tumors. Methods: Prostatic fluid samples were prospectively collected from 40 patients following digital rectal exam and isolated cell-free DNA to perform whole genome methylation sequenc

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!